{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["71(1)"],"submitter":["Bril V"],"funding":["Grifols Therapeutics LLC"],"pubmed_abstract":["Introduction/aims
Prospective, randomized, controlled trials of intravenous immunoglobulin (IVIG) maintenance therapy in myasthenia gravis (MG) are lacking. In this trial, we evaluated the safety and efficacy of caprylate/chromatography-purified IVIG; (IGIV-C) in patients with generalized MG undergoing standard care.Methods
Sixty-two patients enrolled in this phase 2, multicenter, international, randomized trial (1:1 IGIV-C [2 g/kg loading dose; 1 g/kg every 3 weeks through week 21] or placebo). Efficacy was assessed by changes in Quantitative MG (QMG) score at week 24 versus baseline (primary endpoint) and percentage of patients with clinical improvement in QMG, MG Composite (MGC), and MG-Activities of Daily Living (MG-ADL) scores (secondary endpoints). Safety assessments "],"journal":["Muscle & nerve"],"pagination":["43-54"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11632570"],"repository":["biostudies-literature"],"pubmed_title":["Efficacy and safety of maintenance intravenous immunoglobulin in generalized myasthenia gravis patients with acetylcholine receptor antibodies: A multicenter, double-blind, placebo-controlled trial."],"pmcid":["PMC11632570"],"pubmed_authors":["Rivner M","Dalakas MC","Nicolle MW","Magnus T","Reuner U","Freimer M","Griffin R","Toomsoo T","Bril V","Vecsei L","Bednarik J","Mozaffar T","Pascuzzi RM","Souayah N","Szczudlik A","Berkowicz T","Levine T","Pasnoor M","Coll MQ","Panczel G","Vu T","Rozsa C","Mondou E","Hon P","Vaitkus A"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy and safety of maintenance intravenous immunoglobulin in generalized myasthenia gravis patients with acetylcholine receptor antibodies: A multicenter, double-blind, placebo-controlled trial.","description":"Introduction/aims
Prospective, randomized, controlled trials of intravenous immunoglobulin (IVIG) maintenance therapy in myasthenia gravis (MG) are lacking. In this trial, we evaluated the safety and efficacy of caprylate/chromatography-purified IVIG; (IGIV-C) in patients with generalized MG undergoing standard care.Methods
Sixty-two patients enrolled in this phase 2, multicenter, international, randomized trial (1:1 IGIV-C [2 g/kg loading dose; 1 g/kg every 3 weeks through week 21] or placebo). Efficacy was assessed by changes in Quantitative MG (QMG) score at week 24 versus baseline (primary endpoint) and percentage of patients with clinical improvement in QMG, MG Composite (MGC), and MG-Activities of Daily Living (MG-ADL) scores (secondary endpoints). Safety assessments ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jan","modification":"2026-07-15T10:58:37.606Z","creation":"2025-04-04T01:19:59.793Z"},"accession":"S-EPMC11632570","cross_references":{"pubmed":["39506903"],"doi":["10.1002/mus.28289"]}}